Phase 4 Myeloma Trial, Recruiting NCT05722405 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Myeloma
Back to Myeloma

Phase 4 Myeloma Trial, Recruiting

NCT05722405
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with multiple myeloma that is causing symptoms and has certain high-risk genetic features (confirm with trial site for specific features)
  • You are between 18 and 80 years old
  • You are able to carry out basic daily activities, even if you have some limitations due to your illness (confirm with trial site)
  • You have already completed a standard course of treatment called VRD, which may or may not have included a stem cell transplant, and are now ready to receive maintenance (ongoing) therapy
  • Your doctors expect you to live for at least 6 more months
  • Your kidneys, liver, heart, and lungs are working well enough to meet the trial's minimum requirements
  • If you are a woman who could become pregnant, you have had a negative pregnancy test before joining
  • You are willing and able to follow the trial plan as required
  • You are willing to sign a consent form saying you understand and agree to take part

Who may not be able to join:

  • You currently have an infection that is not under control or requires antibiotics given through a drip/IV
  • You are known to have HIV, active hepatitis B, or hepatitis C (though successfully treated hepatitis B or C with no detectable virus may be allowed — confirm with trial site)
  • You have had a blood clot (such as a deep vein thrombosis or pulmonary embolism) in the past 6 months
  • You have had another type of cancer in the last 3 years (some very early-stage cancers may be exceptions — confirm with trial site)
  • You have had serious heart problems such as a heart attack, stent, unstable chest pain, or uncontrolled irregular heartbeat within the past 12 months
  • You have a significant problem with your immune system that is not related to your myeloma
  • You have any other medical condition that could affect how the trial treatment works or how safe it is for you
  • You have previously had a severe allergic reaction to the drug being studied in this trial
  • You are currently pregnant or breastfeeding
  • You are unwilling to use reliable contraception from the time of signing the consent form until 6 months after finishing the treatment
  • Your doctor does not think you will be able to complete all the required visits and procedures
  • You have had an autoimmune disease (such as rheumatoid arthritis, lupus, or Crohn's disease) in the past 2 years that has damaged organs or required strong immune-suppressing medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Yang Xu, Dr., Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: (086)571-89713679

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov